News | November 10, 2021
US govt places additional order of 1.4 million courses of molnupiravir
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
Subscribe To Our Newsletter & Stay Updated
